These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 504992)

  • 1. Movement disorders of aged rats: reversal by dopamine receptor stimulation.
    Marshall JF; Berrios N
    Science; 1979 Oct; 206(4417):477-9. PubMed ID: 504992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of dopaminergic and serotonergic mechanisms in the development of swimming ability of young rats.
    Tamásy V; Korányi L; Phelps CP
    Dev Neurosci; 1981; 4(5):389-400. PubMed ID: 7327101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The short-duration response to apomorphine: implications for the mechanism of dopaminergic effects in parkinsonism.
    Gancher ST; Woodward WR; Gliessman P; Boucher B; Nutt JG
    Ann Neurol; 1990 Jun; 27(6):660-5. PubMed ID: 2360803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired activity of the supplementary motor area in akinetic patients with Parkinson's disease. Improvement by the dopamine agonist apomorphine.
    Rascol OJ; Sabatini U; Chollet F; Montastruc JL; Marc-Vergnes JP; Rascol A
    Adv Neurol; 1993; 60():419-21. PubMed ID: 8420165
    [No Abstract]   [Full Text] [Related]  

  • 5. [Modification of extrapyramidal signs by apomorphine associated with various dopaminergic antagonists].
    Pollak P; Gaio JM; Hommel M; Pellat J; Perret J; Chateau R
    Rev Neurol (Paris); 1982; 138(5):409-13. PubMed ID: 7146725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neostriatal dopamine uptake and reversal of age-related movement disorders with dopamine-uptake inhibitors.
    Altar CA; Marshall JF
    Ann N Y Acad Sci; 1988; 515():343-54. PubMed ID: 3364894
    [No Abstract]   [Full Text] [Related]  

  • 7. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.
    Verhagen Metman L; Locatelli ER; Bravi D; Mouradian MM; Chase TN
    Neurology; 1997 Feb; 48(2):369-72. PubMed ID: 9040723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Chase TN
    Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine receptor dysregulation in hippocampus of aged rats underlies chronic pulsatile L-Dopa treatment induced cognitive and emotional alterations.
    Hernández VS; Luquín S; Jáuregui-Huerta F; Corona-Morales AA; Medina MP; Ruíz-Velasco S; Zhang L
    Neuropharmacology; 2014 Jul; 82():88-100. PubMed ID: 24291463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D1/D2 coactivation induces potentiated responses.
    Weick BG; Walters JR
    Brain Res; 1987 Mar; 405(2):234-46. PubMed ID: 2952219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recovery of function after mesotelencephalic dopaminergic injury in senescence.
    Marshall JF; Drew MC; Neve KA
    Brain Res; 1983 Jan; 259(2):249-60. PubMed ID: 6297672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three types of akinesia in the progressive course of Parkinson's disease.
    Narabayashi H
    Adv Neurol; 1993; 60():18-24. PubMed ID: 8093577
    [No Abstract]   [Full Text] [Related]  

  • 13. Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease.
    Vaamonde J; Luquin MR; Obeso JA
    Mov Disord; 1990; 5(3):260-2. PubMed ID: 2388647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Problems arising during chronic treatment with L-dopa for Parkinson's disease: changes in response to treatment.
    Caraceni TA; Girotti F; Giovannini P; Parati E
    J Neural Transm Suppl; 1986; 22():189-99. PubMed ID: 3537210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine receptors and sleep induction in man.
    Bassi S; Albizzati MG; Frattola L; Passerini D; Trabucchi M
    J Neurol Neurosurg Psychiatry; 1979 May; 42(5):458-60. PubMed ID: 448384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The preferential nNOS inhibitor 7-nitroindazole and the non-selective one N(G)-nitro-L-arginine methyl ester administered alone or jointly with L-DOPA differentially affect motor behavior and monoamine metabolism in sham-operated and 6-OHDA-lesioned rats.
    Czarnecka A; Konieczny J; Lenda T; Lorenc-Koci E
    Brain Res; 2015 Nov; 1625():218-37. PubMed ID: 26319690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of levodopa and apomorphine on neuronal population oscillations in the cortico-basal ganglia loop circuit in vivo in experimental parkinsonism.
    Kühn J; Haumesser JK; Beck MH; Altschüler J; Kühn AA; Nikulin VV; van Riesen C
    Exp Neurol; 2017 Dec; 298(Pt A):122-133. PubMed ID: 28893517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine and L-dopa: inhibition of thyrotropin-stimulated thyroidal thyroxine release.
    Maayan ML; Sellitto RV; Volpert EM
    Endocrinology; 1986 Feb; 118(2):632-6. PubMed ID: 2867890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Duality of dopaminergic receptors. Pharmacologic and clinical perspectives].
    Marais C
    Sem Hop; 1978 May; 54(13-16):563-7. PubMed ID: 211603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine.
    Breese GR; Baumeister AA; McCown TJ; Emerick SG; Frye GD; Crotty K; Mueller RA
    J Pharmacol Exp Ther; 1984 Nov; 231(2):343-54. PubMed ID: 6149306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.